£3116

FGF Receptor 2 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity:	Sensitivity: Endogenous	MW (kDa): 145	Source/Isotype: Rabbit	UniProt ID: #P21802	Entrez-Gene Id: 2263
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		FGF Receptor 2 Antibody detects endogenous levels of total FGF receptor 2 protein. It does not cross-react with other FGF receptor family members.				
Species predicted to react based on 100% sequence homology		Mouse, Rat				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the sequence around Pro38 of human FGF receptor 2. Antibodies are purified by protein A and peptide affinity chrmatography.				
Background		through cell surface r FGFR1 (flg), FGFR2 (be binding domain, a tra binding and dimeriza tyrosine residues in tl 730, and 766. Tyr653 for signaling (3). The	eceptor tyrosine kir ek, KGFR), FGFR3, ar insmembrane doma tion, the receptors he cytoplasmic tail o and Tyr654 are imp other phosphorylat	mitogenic and angiogenases. There are four mend FGFR4. Each receptorain, and a cytoplasmic king phosphorylated at spot FGFR1 can be phosphortant for catalytic activitied tyrosine residues magnas Crk and PLCγ (4,5).	embers of the FGF r contains an extrace nase domain (1). Fo pecific tyrosine resio prylated: Tyr463, 58 ity of activated FGFI	eceptor family: ellular ligand- illowing ligand dues (2). Seven 3, 585, 653, 654, R and are essential
		FGFR-2 has several splicing isoforms, with ligand specificity largely determined by alternative splicing of exons 8 (IIIb) and 9 (IIIc). Alternative splicing is cell type specific, resulting in isoforms showing various tissue distribution and biological activities (6,7). Mutations in the corresponding FGFR-2 gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Grata Syndrome, Pfieffer Syndrome, Apert Syndrome and Jackson-Weiss Syndrome. Mutations and altered expression of FGFR-2 may also be seen in cases of gastric, endometrial and breast cancer (8).				
Background References		1. Powers, C.J. et al. (2000) Endocr Relat Cancer 7, 165-97. 2. Reilly, J.F. et al. (2000) J Biol Chem 275, 7771-8. 3. Mohammadi, M. et al. (1996) Mol Cell Biol 16, 977-89. 4. Mohammadi, M. et al. (1991) Mol Cell Biol 11, 5068-78. 5. Larsson, H. et al. (1999) J Biol Chem 274, 25726-34. 6. Muh, S.J. et al. (2002) J Biol Chem 277, 50143-54. 7. Coutts, J.C. and Gallagher, J.T. (1995) Immunol Cell Biol 73, 584-9. 8. Eswarakumar, V.P. et al. (2005) Cytokine Growth Factor Rev 16, 139-49.				

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.